CTI BioPharma (CTIC) PT Raised to $12 at Brookline Capital Markets Following FDA Approval

Increasing unusual option volume: MULN EQNR APLS WEAT CTIC

Increasing unusual option volume: MULN EQNR APLS WEAT CTIC

Pre-Open Stock Movers 03/01: (CTIC) (TGT) (DDD) Higher; (GDRX) (VRM) (AMBA) Lower (more...)

Pre-Open Stock Movers:

CTI BioPharma Corp. (Nasdaq: CTIC) 54% HIGHER; announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 Ã-109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1. The recommended dosage of VONJO is 200 mg orally twice daily. VONJO is the... More

CTI BioPharma (CTIC) Climbs 37% Following Accelerated FDA Approval of VONJO

CTI BioPharma (NASDAQ: CTIC) Climbs 37% Following Accelerated FDA Approval of VONJO

Stifel Reiterates Buy Rating on CTI BioPharma (CTIC), Expects Stock to Trade Up Substantially on Vonjo Approval

Stifel analyst Benjamin Burnett reiterated a Buy rating on CTI BioPharma (NASDAQ: CTIC), following approval of the company's Vonjo drug.

The analyst quotes: "We reiterate our Buy rating on CTIC following the approval of Vonjo (pacritinib) for the treatment of myelofibrosis patients with severe thrombocytopenia.... More

CTI BioPharma (CTIC) Granted FDA Accelerated Approval of VONJO

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1. The recommended dosage of VONJO is 200 mg orally twice daily. VONJO is the first approved therapy that specifically addresses the needs of patients with cytopenic myelofibrosis.

"Today's approval of VONJO establishes a new standard of... More